BioDiem licenses vaccine tech to China's BCHT
13 February, 2012 by Dylan Bushell-EmblingMelbourne biotech BioDiem (ASX:BDM) has awarded Changchun BCHT an exclusive license for the China private sector market covering its influenza vaccine technology.
Bioniche reports loss, focuses on animal health
10 February, 2012 by Dylan Bushell-EmblingDual-listed biopharma Bioniche (ASX:BNC) has posted a Q2 loss of $4m, and shareholders have been warned the company may have inadequate cash reserves for the next 12 months.
Trial shows Patrys melanoma antibody safe
10 February, 2012 by Dylan Bushell-EmblingMelbourne's Patrys Limited (ASX:PAB) has successfully concluded a safety and tolerability trial for its lead antibody, PAT-SM6, as a melanoma treatment.
Program released for annual business development forum
09 February, 2012 by AusBiotechAusBiotech has today launched the speaking program for the business development meeting of the year, to be held on the Gold Coast from 15-16 March.
Cochlear posts $20m loss on recall costs
08 February, 2012 by Dylan Bushell-EmblingCochlear (ASX:COH) has posted a $20.4 million net loss for the first half of this financial year, with earnings impacted by a major recall as well as forex losses.
Clinuvel files for marketing approval for SCENESSE in Europe
07 February, 2012 by Dylan Bushell-EmblingMelbourne-based Clinuvel (ASX:CUV) has applied for the right to market its SCENESSE subdermal treatment in the EU as a treatment for erythropoietic protoporphyria.
Alchemia making US inroads with coagulant
07 February, 2012 by Dylan Bushell-EmblingAlchemia Limited has revealed it is now selling more than $1.4 million per week worth of its lead drug, fondaparinux, in the US.
AusBiotech linked in to the industry network
07 February, 2012 by AusBiotechAusBiotech's two groups on social networking site LinkedIn have grown rapidly in the past year, this week reaching more than 1500 members (combined), cementing their place as the largest networks of their kind for Australian biotechnology and medical technology.
Prima enrols first patient for cancer trial
06 February, 2012 by Dylan Bushell-EmblingSydney's Prima BioMed (ASX:PRR) has enrolled the first participant for an 800-member trial of its CVac ovarian cancer treatment in post-chemotherapy patients.
Biotechs recover from slump in Q2
03 February, 2012 by Dylan Bushell-EmblingAustralia's life science industry performed relatively well in the December 2011 quarter despite macroeconomic pressures, according to the PricewaterhouseCoopers BioForum Report, with indicators good for the near future.
AusBiotech submits on R&D Tax Incentive Discussion Paper
02 February, 2012 by AusBiotechAusBiotech has lodged a submission in response to the ‘Discussion Paper: R&D Tax Incentive Implementation – realising effective Compliance through Guidance and Education’, which was been conducted by AusIndustry to inform development of its guidance agenda.
Starpharma stocks rise on positive cancer trial results
02 February, 2012 by Dylan Bushell-EmblingStarpharma Holdings (ASX:SPL) shares climbed 12.4% on Wednesday, after the release of positive results from a preclincial study of its dendrimer-docetaxel chemotherapy formulation.
Bionomics deal could push cashflow into black
02 February, 2012 by Dylan Bushell-EmblingThe initial $3m Bionomics has received from its drug development deal with Ironwood Pharmaceuticals could help speed an improvement in cashflow.
Immuron, Monash partner to develop colostrum therapy
31 January, 2012 by Dylan Bushell-EmblingMelbourne-based Immuron (ASX:IMC) and Monash University will collaborate on products aimed at treating C. difficile infections, using Immuron's colostrum technology.
Ascent sold to Watson for $375m
31 January, 2012 by Tim DeanIndian pharmaceutical company Strides Arcolab has sold its Australian generic pharmaceutical manufacturer Ascent Pharmahealth to Watson Pharmaceutical.
